Cerus (NASDAQ: CERS) is one of 19 public companies in the “Medical Devices & Implants” industry, but how does it weigh in compared to its rivals? We will compare Cerus to similar companies based on the strength of its valuation, profitability, analyst recommendations, dividends, earnings, institutional ownership and risk.
This table compares Cerus and its rivals’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
This table compares Cerus and its rivals revenue, earnings per share and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|Cerus||$39.28 million||-$62.90 million||-6.32|
|Cerus Competitors||$1.67 billion||$207.58 million||80.89|
Cerus’ rivals have higher revenue and earnings than Cerus. Cerus is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.
Insider and Institutional Ownership
58.5% of Cerus shares are owned by institutional investors. Comparatively, 54.8% of shares of all “Medical Devices & Implants” companies are owned by institutional investors. 7.4% of Cerus shares are owned by insiders. Comparatively, 11.9% of shares of all “Medical Devices & Implants” companies are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
Risk & Volatility
Cerus has a beta of 1.93, meaning that its stock price is 93% more volatile than the S&P 500. Comparatively, Cerus’ rivals have a beta of 0.47, meaning that their average stock price is 53% less volatile than the S&P 500.
This is a summary of recent ratings and recommmendations for Cerus and its rivals, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Cerus currently has a consensus price target of $6.60, suggesting a potential upside of 76.94%. As a group, “Medical Devices & Implants” companies have a potential upside of 36.66%. Given Cerus’ stronger consensus rating and higher probable upside, equities research analysts clearly believe Cerus is more favorable than its rivals.
Cerus rivals beat Cerus on 7 of the 12 factors compared.
Cerus Corporation is a biomedical products company. The Company is engaged in developing and commercializing the INTERCEPT Blood System for blood safety. The Company operates through blood safety segment. The Company’s INTERCEPT Blood System is based on its technology for controlling biological replication, and is designed to reduce blood-borne pathogens in donated blood components intended for transfusion. The Company’s INTERCEPT Blood System is designed to target and inactivate blood-borne pathogens, such as viruses, including human immunodeficiency virus (HIV), West Nile, Severe acute respiratory syndrome (SARS), hepatitis B and C; bacteria and parasites, as well as harmful white blood cells, while preserving the therapeutic properties of platelet, plasma and red blood cell transfusion products. The Company’s INTERCEPT Blood System is for use with blood components, including plasma, platelets, and red blood cells.
What are top analysts saying about Cerus Corporation? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Cerus Corporation and related companies.